Andrea Di-Luserna

San Giuliano Terme, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions.

Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions.

Journal: Journal of translational medicine

Published: July 09, 2024

ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment.

ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment.

Journal: International journal of molecular sciences

Published: October 27, 2023

Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients.

Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 18, 2023

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations.

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations.

Journal: Frontiers in cell and developmental biology

Published: February 13, 2023

Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon.

Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon.

Journal: Molecules (Basel, Switzerland)

Published: November 04, 2022

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin.

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin.

Journal: Cancers

Published: August 19, 2021

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma.

CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma.

Journal: Cancers

Published: April 23, 2021

Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.

Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.

Journal: Leukemia

Published: March 11, 2021

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a.

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a.

Journal: Biomedicines

Published: March 01, 2021

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia.

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia.

Journal: Journal for immunotherapy of cancer

Published: January 17, 2021

Synthesis of Novel Tryptamine Derivatives and Their Biological Activity as Antitumor Agents.

Synthesis of Novel Tryptamine Derivatives and Their Biological Activity as Antitumor Agents.

Journal: Molecules (Basel, Switzerland)

Published: December 31, 2020

Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation.

Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation.

Journal: International journal of molecular sciences

Published: November 18, 2020

Showing 1-12 of 27

Last Updated: 09/26/2026